[1] El-Ziny MA, Salem NA, El-Hawary AK, et al. Epidemiology of childhood type 1 diabetes mellitus in Nile Delta, northern Egypt - a retrospective study. J Clin Res Pediatr Endocrinol. 2014;6(1):9-15.
[2] van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011;91(1):79-118.
[3] Zóka A, Somogyi A, Firneisz G. Type 1 diabetes mellitus: most recent advances in its pathogenesis and treatment. Orv Hetil. 2012;153(27):1047-1056.
[4] Patelarou E, Girvalaki C, Brokalaki H, et al. Current evidence on the associations of breastfeeding, infant formula, and cow's milk introduction with type 1 diabetes mellitus: a systematic review. Nutr Rev. 2012;70(9):509-519.
[5] Morran MP, Vonberg A, Khadra A, et al. Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med. 2015;42:42-60.
[6] Martinez PJ, Mathews C, Actor JK, et al. Impaired CD4+ and T-helper 17 cell memory response to Streptococcus pneumoniae is associated with elevated glucose and percent glycated hemoglobin A1c in Mexican Americans with type 2 diabetes mellitus. Transl Res. 2014;163(1):53-63.
[7] Michalek J, Vrabelova Z, Hrotekova Z, et al. Immune regulatory T cells in siblings of children suffering from type 1 diabetes mellitus. Scand J Immunol. 2006;64(5):531-535.
[8] Szablewski L. Role of immune system in type 1 diabetes mellitus pathogenesis. Int Immunopharmacol. 2014; 22(1): 182-191.
[9] Li M, Song LJ, Qin XY. Advances in the cellular immunological pathogenesis of type 1 diabetes. J Cell Mol Med. 2014;18(5): 749-758.
[10] Adamson KA, Cheetham TD, Kendall-Taylor P, et al. The role of the IDDM2 locus in the susceptibility of UK APS1 subjects to type 1 diabetes mellitus. Int J Immunogenet. 2007;34(1): 17-21.
[11] Zóka A, Barna G, Somogyi A, et al. Extension of the CD4+Foxp3+CD25-/low regulatory T-cell subpopulation in type 1 diabetes mellitus. Autoimmunity. 2014:1-9.
[12] Fridell JA, Rogers J, Stratta RJ. The pancreas allograft donor: current status, controversies, and challenges for the future. Clin Transplant. 2010;24(4):433-449.
[13] Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105(3):369-377.
[14] Lin PY, Hung SH, Yang YC, et al. A synthetic peptide-acrylate surface for production of insulin-producing cells from human embryonic stem cells. Stem Cells Dev. 2014;23(4):372-379.
[15] Kahan BW, Jacobson LM, Hullett DA, et al. Pancreatic precursors and differentiated islet cell types from murine embryonic stem cells: an in vitro model to study islet differentiation. Diabetes. 2003;52(8):2016-2024.
[16] Brolén GK, Heins N, Edsbagge J, et al. Signals from the embryonic mouse pancreas induce differentiation of human embryonic stem cells into insulin-producing beta-cell-like cells. Diabetes. 2005;54(10):2867-2874.
[17] Kwon YD, Oh SK, Kim HS, et al. Cellular manipulation of human embryonic stem cells by TAT-PDX1 protein transduction. Mol Ther. 2005;12(1):28-32.
[18] Xiao X, Chen Z, Shiota C, et al. No evidence for β cell neogenesis in murine adult pancreas. J Clin Invest. 2013; 123(5):2207-2217.
[19] Calafiore R, Montanucci P, Basta G. Stem cells for pancreatic β-cell replacement in diabetes mellitus: actual perspectives. Curr Opin Organ Transplant. 2014;19(2):162-168.
[20] Szot GL, Yadav M, Lang J, et al. Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm. Cell Stem Cell. 2015;16(2):148-157.
[21] Cavelti-Weder C, Shtessel M, Reuss JE, et al. Pancreatic duct ligation after almost complete β-cell loss: exocrine regeneration but no evidence of β-cell regeneration. Endocrinology. 2013;154(12):4493-4502.
[22] Lee KO, Gan SU, Calne RY. Stem cell therapy for diabetes. Indian J Endocrinol Metab. 2012;16(Suppl 2):S227-229.
[23] Aali E, Mirzamohammadi S, Ghaznavi H, et al. A comparative study of mesenchymal stem cell transplantation with its paracrine effect on control of hyperglycemia in type 1 diabetic rats. J Diabetes Metab Disord. 2014;13(1):76.
[24] Mesples A, Majeed N, Zhang Y, et al. Early immunotherapy using autologous adult stem cells reversed the effect of anti-pancreatic islets in recently diagnosed type 1 diabetes mellitus: preliminary results. Med Sci Monit. 2013;19: 852-857.
[25] Li M, Ikehara S. Bone-marrow-derived mesenchymal stem cells for organ repair. Stem Cells Int. 2013;2013:132642.
[26] Malgieri A, Kantzari E, Patrizi MP, et al. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med. 2010;3(4):248-269.
[27] Trivedi HL, Vanikar AV, Thakker U, et al. Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. Transplant Proc. 2008;40(4):1135-1139.
[28] Pan XH, Song QQ, Dai JJ, et al. Transplantation of bone marrow mesenchymal stem cells for the treatment of type 2 diabetes in a macaque model. Cells Tissues Organs. 2013; 198(6):414-427.
[29] Ianus A, Holz GG, Theise ND, et al. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest. 2003; 111(6):843-850.
[30] Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297 (14):1568-1576.
[31] Karaoz E, Okcu A, Ünal ZS, et al. Adipose tissue-derived mesenchymal stromal cells efficiently differentiate into insulin-producing cells in pancreatic islet microenvironment both in vitro and in vivo. Cytotherapy. 2013;15(5):557-570.
[32] Teichert AM, Pereira S, Coles B, et al. The neural stem cell lineage reveals novel relationships among spermatogonial germ stem cells and other pluripotent stem cells. Stem Cells Dev. 2014;23(7):767-778.
[33] Morimoto H, Iwata K, Ogonuki N, et al. ROS are required for mouse spermatogonial stem cell self-renewal. Cell Stem Cell. 2013;12(6):774-786.
[34] Guo XR, Wang XL, Li MC, et al. PDX-1 mRNA-induced reprogramming of mouse pancreas-derived mesenchymal stem cells into insulin-producing cells in vitro. Clin Exp Med. 2014 Oct 28. [Epub ahead of print]
[35] Godfrey KJ, Mathew B, Bulman JC, et al. Stem cell-based treatments for Type 1 diabetes mellitus: bone marrow, embryonic, hepatic, pancreatic and induced pluripotent stem cells. Diabet Med. 2012;29(1):14-23.
[36] Li SW, Koya V, Li Y, et al. Pancreatic duodenal homeobox 1 protein is a novel beta-cell-specific autoantigen for type I diabetes. Lab Invest. 2010;90(1):31-39.
[37] Ende N, Chen R, Reddi AS. Effect of human umbilical cord blood cells on glycemia and insulitis in type 1 diabetic mice. Biochem Biophys Res Commun. 2004;325(3):665-669.
[38] Haller MJ, Viener HL, Wasserfall C, et al. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol. 2008;36(6):710-715.
[39] BarNur O, Russ HA, Efrat S, et al. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell. 2011;9(1):17-23.
[40] Kuise T, Noguchi H, Tazawa H, et al. Establishment of a pancreatic stem cell line from fibroblast-derived induced pluripotent stem cells. Biomed Eng Online. 2014;13:64.
[41] Zavazava N. Progress toward establishing embryonic stem or induced pluripotent stem cell-based clinical translation. Curr Opin Organ Transplant. 2014;19(6):598-602.
[42] Golestaneh N, Kokkinaki M, Pant D, et al. Pluripotent stem cells derived from adult human testes. Stem Cells Dev. 2009; 18(8):1115-1126. |